SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) — NKGen Biotech, a biotechnology firm harnessing the facility of the physique’s immune system via the event of Pure Killer (NK) cell therapies, in the present day introduced that it has appointed Philip Moody as its Chief Monetary Officer (CFO). Mr. Moody is a extremely completed CFO who brings vital monetary management expertise to NKGen Biotech.
“I’m thrilled to welcome Philip to our management staff,” mentioned Stephen Chen, Chief Working Officer. “His intensive expertise in monetary operations, company technique and capital markets entry will make a direct constructive impression throughout this progress section in our firm and place NKGen Biotech properly for the long run.”
Mr. Moody has 25 years of broad healthcare and biotech trade management expertise. He was CFO and Government Vice President of PaxVax, a personal equity-backed specialty vaccine firm. Previous to PaxVax, Mr. Moody was CFO, North America for BTG PLC, a publicly traded medical machine and specialty pharmaceutical firm that was acquired by Boston Scientific. Moreover, he served as CFO and Vice President of Finance and Operations for publicly traded Peplin, Inc., an oncology therapeutics firm. Mr. Moody started his biotech profession at Chiron Company the place he progressed via roles of accelerating duty to the position of CFO and Senior Vice President of Finance and Operations, Biopharmaceuticals.
“NKGen Biotech has a number one NK cell remedy platform and pipeline, together with a powerful manufacturing facility,” mentioned Mr. Moody. ” I imagine the potential for progress and worth creation is great. It’s a nice time to be becoming a member of the NKGen Biotech staff to additional align monetary technique with its company targets and place the Firm for additional financings.”
Mr. Moody accomplished a BS in Mechanical Engineering from the College of California, Berkley and studied finance at its Haas Graduate College of Enterprise.
About NKGen Biotech
NKGen Biotech is a scientific stage biotechnology firm devoted to restoring and enhancing total immune integrity. Our proprietary pure killer cell growth and activation expertise achieves infinite fold pure killer cell growth with enormously enhanced cytotoxicity throughout each autologous and allogenic merchandise that are all derived from peripheral blood. Our first in school autologous product, SNK01, is at present in a Section I scientific trial in superior refractory strong tumors and in a Section I/IIa mixture trial with pembrolizumab in Stage IV non-small cell lung most cancers. We have now additionally added one other cohort of SNK01 together with pembrolizumab or avelumab in refractive PD-L1 constructive or PD-L1 detrimental strong tumors and are planning to provoke a Section 1 mixture trial of SNK01 and AFM24 in EGFR constructive strong tumors. The corporate and its commercially licensed cGMP facility are headquartered in Santa Ana, California, USA. http://www.nkgenbiotech.com/
Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Advertising
949-396-6830
dchua@nkgenbiotech.com
